Maravai LifeSciences (MRVI) Competitors $5.70 -0.08 (-1.38%) (As of 11/12/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MRVI vs. MDGL, ASND, LEGN, JAZZ, VKTX, ELAN, CYTK, BPMC, NUVL, and CORTShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Madrigal Pharmaceuticals (MDGL), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Jazz Pharmaceuticals (JAZZ), Viking Therapeutics (VKTX), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Nuvalent (NUVL), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry. Maravai LifeSciences vs. Madrigal Pharmaceuticals Ascendis Pharma A/S Legend Biotech Jazz Pharmaceuticals Viking Therapeutics Elanco Animal Health Cytokinetics Blueprint Medicines Nuvalent Corcept Therapeutics Madrigal Pharmaceuticals (NASDAQ:MDGL) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Does the media prefer MDGL or MRVI? In the previous week, Maravai LifeSciences had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 23 mentions for Maravai LifeSciences and 20 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.82 beat Maravai LifeSciences' score of 0.10 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend MDGL or MRVI? Madrigal Pharmaceuticals presently has a consensus price target of $347.33, indicating a potential upside of 2.79%. Maravai LifeSciences has a consensus price target of $10.33, indicating a potential upside of 84.85%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Maravai LifeSciences 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk and volatility, MDGL or MRVI? Madrigal Pharmaceuticals has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Is MDGL or MRVI more profitable? Madrigal Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.25% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal PharmaceuticalsN/A -71.78% -53.25% Maravai LifeSciences -81.13%-6.25%-3.35% Which has stronger earnings and valuation, MDGL or MRVI? Maravai LifeSciences has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal PharmaceuticalsN/AN/A-$373.63M-$25.08-13.47Maravai LifeSciences$288.95M4.88-$119.03M-$1.64-3.41 Do institutionals & insiders have more ownership in MDGL or MRVI? 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in MDGL or MRVI? Madrigal Pharmaceuticals received 395 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 67.80% of users gave Madrigal Pharmaceuticals an outperform vote while only 64.58% of users gave Maravai LifeSciences an outperform vote. CompanyUnderperformOutperformMadrigal PharmaceuticalsOutperform Votes45767.80% Underperform Votes21732.20% Maravai LifeSciencesOutperform Votes6264.58% Underperform Votes3435.42% SummaryMaravai LifeSciences beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$6.69B$5.18B$8.93BDividend YieldN/A7.99%7.11%4.02%P/E Ratio-3.4111.94135.7418.07Price / Sales4.88275.581,387.9475.31Price / Cash53.5948.5538.6136.30Price / Book1.788.456.146.00Net Income-$119.03M$152.97M$117.07M$223.88M7 Day Performance-28.79%0.17%2.88%3.58%1 Month Performance-30.21%10.98%7.66%7.58%1 Year Performance8.97%48.33%45.03%32.51% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences4.7323 of 5 stars$5.70-1.4%$10.33+81.3%+11.1%$1.44B$288.95M-3.48580Insider BuyingMDGLMadrigal Pharmaceuticals3.9712 of 5 stars$354.85+4.9%N/A+144.2%$7.74BN/A-14.1590ASNDAscendis Pharma A/S3.3363 of 5 stars$126.55-2.2%N/A+41.4%$7.63B$288.08M-13.59640Upcoming EarningsShort Interest ↑LEGNLegend Biotech2.1389 of 5 stars$40.95-1.1%N/A-37.6%$7.47B$455.99M-52.501,800Short Interest ↑News CoverageJAZZJazz Pharmaceuticals4.9417 of 5 stars$119.08+6.8%N/A+6.3%$7.35B$3.83B20.462,800Gap UpHigh Trading VolumeVKTXViking Therapeutics4.5292 of 5 stars$68.85+4.5%N/A+519.6%$7.34BN/A-74.0320ELANElanco Animal Health3.6972 of 5 stars$14.50+12.8%N/A+32.2%$7.17B$4.42B-5.699,300Earnings ReportShort Interest ↑Analyst RevisionCYTKCytokinetics4.0796 of 5 stars$55.84+0.6%N/A+72.9%$6.57B$7.53M-10.40250Earnings ReportAnalyst RevisionNews CoverageBPMCBlueprint Medicines1.0913 of 5 stars$101.39+1.8%N/A+64.2%$6.44B$249.38M-48.05640Short Interest ↑NUVLNuvalent2.2366 of 5 stars$94.09flatN/A+60.1%$6.10BN/A-33.8540Analyst ForecastCORTCorcept Therapeutics4.8048 of 5 stars$54.30+0.1%N/A+130.9%$5.69B$482.38M43.10300Short Interest ↓ Related Companies and Tools Related Companies MDGL Alternatives ASND Alternatives LEGN Alternatives JAZZ Alternatives VKTX Alternatives ELAN Alternatives CYTK Alternatives BPMC Alternatives NUVL Alternatives CORT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRVI) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
